Reprint

Clear Cell Renal Cell Carcinoma 2021–2022

Edited by
October 2022
342 pages
  • ISBN978-3-0365-5517-1 (Hardback)
  • ISBN978-3-0365-5518-8 (PDF)

This book is a reprint of the Special Issue Clear Cell Renal Cell Carcinoma 20212022 that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

Clear cell renal cell carcinoma is currently one of the most interesting areas of study in oncology. Despite the advances made in this field, this tumor continues to be a health problem of major concern in Western societies, seriously affecting public health services. Several characteristics of this tumor make it an exciting meeting point for translational collaboration between clinicians and basic researchers.

Clear cell renal cell carcinoma is a paradigmatic example of inter- and intra-tumor heterogeneity from morphological, immunohistochemical, and molecular viewpoints. This tumor is also a good example to investigate the complexity of tumor/tumor and tumor/environment relationships from an ecological perspective. A deeper identification of the varied internal tumor self-organization through the specialization of cell clones and subclones as local invaders and metastasizers, on one hand, and the interactions of specific subsets of tumor cells with the local host microenvironment, on the other, will significantly enrich our knowledge of this neoplasm.

Clear cell renal cell carcinoma is also a paradigmatic test bench for antiangiogenic and immune checkpoint blockage therapies. The refinement of these therapeutic tools administered alone or in combination is a hot issue in oncology, and several international trials are underway.

Format
  • Hardback
License
© by the authors
Keywords
clear cell renal cell carcinoma; prognosis; plasma; PD-1; PD-L1; renal cell carcinoma; immune checkpoint inhibitors; immune related adverse events (irAEs); thyroid; cutaneous; biomarker; renal cell carcinoma; biomarker; DNA methylation; epigenetics; kidney; hypoxia; tumor microenvironment; SCD-1; oleic acid; renal cancer; sunitinib; resistance; miRNA; transcriptome; pathway analysis; clear cell renal cell carcinoma; nivolumab; clear cell renal cell carcinoma; tissue slice culture; PD1; T-cells; metastatic clear cell renal cell carcinoma; first-line treatment; immunotherapy; tyrosine kinase inhibitors; combinations; single-cell RNA sequencing; immune landscape; cancer immunotherapy; clear cell renal cell carcinoma; clear cell renal cell carcinoma; intra-tumoral heterogeneity; inter-tumoral heterogeneity; inter-metastatic heterogeneity; renal cell cancer; treatment resistance; immunotherapy; angiogenesis; tumor microenvironment; adjuvant therapy; clear cell renal cell carcinoma; biomarker; prediction model; prognostic factor; clear cell kidney cancer; radiogenomics; radiomics; machine learning; gene expression; kidney; cystic tumor; imaging; magnetic resonance; surgery; ddPCR; circulating miRNA; renal cell carcinoma; diagnosis; malignancy; clear cell renal cell carcinoma; histomorphological features; PBRM1; immunohistochemistry; architectural patterns; endothelial cells; radiogenomics; translational; clear cell renal cell carcinoma; renal cell carcinoma; immune checkpoint inhibitor; responsiveness; molecular features; multisite tumor sampling; intratumor heterogeneity; clear cell renal cell carcinoma; gene expression; clear-cell renal cell carcinoma; disease progression; prognostic factors; biomarkers; RNA sequencing; n/a